Your browser doesn't support javascript.
loading
Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.
Cox, Nancy J; Hickling, Julian; Jones, Rebecca; Rimmelzwaan, Guus F; Lambert, Linda C; Boslego, John; Rudenko, Larisa; Yeolekar, Leena; Robertson, James S; Hombach, Joachim; Ortiz, Justin R.
Afiliación
  • Cox NJ; Influenza Division, National Center for Infectious Diseases, 1600 Clifton Road NE, Atlanta, GA 30333, United States.
  • Hickling J; Working in Tandem Ltd, Cambridge CB1 7AB, United Kingdom.
  • Jones R; Working in Tandem Ltd, Cambridge CB1 7AB, United Kingdom.
  • Rimmelzwaan GF; Department of Virology, Erasmus Medical Center, Dr Molewaterplein 50, Rotterdam CE 3015, The Netherlands.
  • Lambert LC; Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, NIAID/NIH/DHHS, 5601 Fishers Lane, Bethesda, MD 20892, United States.
  • Boslego J; PATH, 445 Massachusetts Avenue, NW Suite 1000, Washington, DC 20001, United States.
  • Rudenko L; Institute of Experimental Medicine, Russian Academy of Medical Sciences, 12 Acad. Pavlov Street, St Petersburg 197376, Russian Federation.
  • Yeolekar L; Vaccine Production, Serum Institute of India, 212/2 Hadapsar, Pune, India.
  • Robertson JS; Independent Consultant, St. Albans, United Kingdom.
  • Hombach J; Initiative for Vaccine Research (IVR), Immunization, Vaccines and Biologicals (IVB), World Health Organization, Switzerland.
  • Ortiz JR; Initiative for Vaccine Research (IVR), Immunization, Vaccines and Biologicals (IVB), World Health Organization, Switzerland.
Vaccine ; 33(48): 6503-10, 2015 Nov 27.
Article en En | MEDLINE | ID: mdl-26478203
On 5-7 May 2014, the World Health Organization (WHO) convened the second integrated meeting on "influenza vaccines that induce broadly protective and long-lasting immune responses". Around 100 invited experts from academia, the vaccine industry, research and development funders, and regulatory and public health agencies attended the meeting. Areas covered included mechanisms of protection in natural influenza-virus infection and vaccine-induced immunity, new approaches to influenza-vaccine design and production, and novel routes of vaccine administration. A timely focus was on how this knowledge could be applied to both seasonal influenza and emerging viruses with pandemic potential such as influenza A (H7N9), currently circulating in China. Special attention was given to the development of possible universal influenza vaccines, given that the Global Vaccine Action Plan calls for at least one licensed universal influenza vaccine by 2020. This report highlights some of the topics discussed and provides an update on studies published since the report of the previous meeting.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana Límite: Animals / Humans Idioma: En Revista: Vaccine Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana Límite: Animals / Humans Idioma: En Revista: Vaccine Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos